Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The devotion to surrogate outcomes in drug development for liver disease

Nature Reviews Gastroenterology & Hepatology volume 15, pages 1–2 (2018)Cite this article

Subjects

Surrogate end points are often used in clinical trials where the time to clinical outcomes is long. In patients with liver disease, these surrogate outcomes are rarely validated. Without validation, treatment effects reported in trials might not directly translate to patient benefit after licensing.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Yudkin, J. S., Lipska, K. J. & Montori, V. M. The idolatry of the surrogate. BMJ 343, d7995 (2011).

    Article  Google Scholar 

  2. Sanyal, A. J. et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop. Hepatology 61, 1392–1405 (2015).

    Article  Google Scholar 

  3. Jakobsen, J. C. et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst. Rev. 6, CD012143 (2017).

    PubMed  Google Scholar 

  4. Innes, H. A. et al. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. Hepatology 57, 451–460 (2013).

    Article  Google Scholar 

  5. Sanyal, A. J. et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54, 344–353 (2011).

    Article  Google Scholar 

  6. Hagstrom, H. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J. Hepatol. http://dx.doi.org/10.1016/j.jhep.2017.07.027 (2017).

  7. Friedman, S. L. et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology http://dx.doi.org/10.1002/hep.29477 (2017).

  8. Loomba, R. et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology http://dx.doi.org/10.1002/hep.29514 (2017).

  9. Parker, R., Hodson, J. & Rowe, I. A. Systematic review: Current evidence in non-alcoholic fatty liver disease lacks relevance to patients with advanced fibrosis. J. Gastroenterol. Hepatol. 32, 950–956 (2016).

    Article  Google Scholar 

  10. Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease — Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leeds Institute for Data Analytics, Room 6.1 Clinical Sciences Building, University of Leeds, St. James's Hospital, Leeds, LS9 7TF, UK

    Ian A. Rowe

Authors
  1. Ian A. Rowe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian A. Rowe.

Ethics declarations

Competing interests

I.A.R. has received honoraria for speaking at sponsored meetings from AbbVie and Bayer Healthcare outside the submitted work.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rowe, I. The devotion to surrogate outcomes in drug development for liver disease. Nat Rev Gastroenterol Hepatol 15, 1–2 (2018). https://doi.org/10.1038/nrgastro.2017.155

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2017.155

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research